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It has been demonstrated in various human and animal 
models that sudden increases in right atrial pressure induce 
the release at atrial natriuretic factor (I-8). Rapid ventricular 
pacing in patients with sinus rhythm proved t@ be a re!iable 
and @tTective methcd to provoke short-term increment iii 
right atrial pressure as well as in atrial natriuretic factor (9). 
Little is kmwn about the cellular mechanisms involved in 
the mediation d the release of atrial natriuretic factor. In 
vitro experiments (10-12) suggest that secretion of atrial 
nattiurelic factor is a calcium-depmdent process because 
Bay K&44. a v&age-sensitive calcium channel actiwtur, 
induced a sustained increase in the s@cr@tory ate of atrial 
nalriuretic factor. This effect was abolished by simullaneous 
administmtion of nifedipine, a competitive calcium channel 
blocker (10). 
These observations prompted us to examine whsther the 
release of atnal narrhuetic factor in patients could be sup 
pressed by administration of a calcium antagonist. In a 
recently pubhshed study (13) it was demonstrated that 
verapamil did not alter basal cmcentrations of atrial natri- 
uretic factor in rats, whereas in tw pad@nts with essential 
hypertension who had elevated levels of atrial natriurelic 
fac:or. a decline of the Secretion rate of atrial nalriur@lic 
factor and blwd pressure was observed @fter 2 weeks of 
therapy with nifedipim (14). A differentiation between P 
dirxt influence of-nifedipine on the secretion of atria1 
natriuretic factor or nn indirect effect due to the drop in 
systemi@ arterial blood pressure was not possible. Tk 
present study was designedtoinvestigate heinfluenceafthe 
calcium antagonist verqmil on the ~ecretiw of atrial 
oatriuretic factor induced by a sudden increment in right 
&al prCsE”r@. 
Stray pslhnts. Sixrem patients (5 female, il male, aged 
3% to 66 y@an) with m&rate coronary artery diseas@ w@r@ 
studied during diagnostic right and left heart catheterization 
before left ventriwlar and coronary angiography. All pa- 
tients h?d mrmal ventricular and atrial pressures. a Iel? 
ventricular ejection fraction 24% and stable sinus rhythm 
at rest. hdministmtion of nitrates. beta-receptor blocking 
agents and calcium channel antagonists was te~minatcd 248 
h before the examination. None of lhe patients was receiving 
digitalis. All patients had given informed consent. 
Fwtocol. As we have shown in a previous study (9). right 
ventricular pacing in patients with sinus rhythm results in 
asynchronous contraction of the righl ventricle and right 
atrium and leads to a sudden increment in right atrial 
pressure and subsequently to an increase in concentrations 
bf ol8sma atrial nslriuretic factor. 
jhc parienu ware cln.rs$ed inro two groups: Group I (n 
= 8) underwent right ventricular pacing at 150 beatslmin for 
a period of4 min (&v&ion Il. After a I5 min interval. the 
identical stimulation was repeated (stimulation II). Patients 
of Group 2 (n = 8) were subjected to the same protocol 
except that they received vetapamil. 5 mg intravenously, at 
the beginning of the I5 min interval after stimulation 1. In all 
patients, right atrial pressure and systemic blood pressure 
were continuously measured through catheters placed in the 
rigbi atrium and ;he femoral ale&, respeclively. A bipolar 
lead placed in the apex of the right ventricle and a program- 
mable external pacemaker were used for stimulation. The 
electrocardiogram (ECG) was monitored throughout the 
study. 
Plasma radIoImmurmpsssy. Arterial blcud samples were 
taken in ice water-cooled ethylenediaminetetraacetate ubes 
before and after stimulation 1 and 11 and immediately sepa- 
rated by centrifugalion at TC and 2,800 rpm and stored at 
-7O’C until assayed. Plasma concentration of atria1 natri- 
uretic factor was measured by mdioimmunoassay after ex- 
traction through ODS-silica cartridges according to ti!r pro- 
cedure described for rat and human plasma samples (15). 
Plasma levels of cyclic guanosine monopbospbate (GMP) 
were measured by radioimmunoassay of ethanol-extracted 
samples (5). 
FiQre I. Etiect of right vemricular stimulation (Slim) I and II (both 
for 4 mire at IS0 bcatslmin) on mean right atrial preswe (RAP 2 
SD). Patients ofaimup I were untreated; Group 2 patients received 
5 mg verapamil intravenously immediately after stimulation I. m = 
not significant. SR = sinus rhythm before bath stimulations. 
Hg during stimulation I and from 4.9 f 1.2 to 7.3 ? 1.6 mm 
Hg during stimulation II. Verapamil did not alter Ihe incrc- 
ment in right atrial pressure. Thus, each time pacing was 
applied, right atria1 pressure increased by a constant amottttt 
independent of the stimulation period (stimulation 1 or II) 
and independent of vcrapamil administration. 
Systemic bbxd praswe. In both gmupa, estimates of 
mean systemic blood pressure were unchanged throughout 
the protocol. Mar. systemic arterial prewre was un- 
changed by either pacing or vcrapamil administration. 
Atrial n&IuretIc factor (Fl& 2). In Group I and Group 2, 
median plasma atrial nalrittretic factor levels rose from 79 
(range 46 to 299) to 258 (range 96 to 1,045) p!&ttl (p < 0.01) 
and from 58 (range 21 lo 171) to 142 (range 90 lo 308) p&t1 
(p < 0.021, respectively, during the first stimulation, that is, 
before verapamil treatment in Group 2. For both groups the 
amount of atrial natriuretic factor increase due to stimulation 
1 showed no statistical difference. 
&tistical snnlysls. The Wilcaxon matched pairs test was 
used for statistical intraindividual evaluation. The Mann- 
Whitney (I test was used for interindividual comparison. 
Probability values CO.05 were considered significant. 
Figwe 2. Atrial natriuretic factor IANFl plasma concentrations 
during stimulation II (Slim II for 4 min at 150 bcatslmin) for each 
patien! in Groups I and 2. Patients of Gmup I were untreated: 
Group 2 bad recriwd 5 ma ol wapamil intravenously. He&awl 
ttnw represent median values. Abbreviations as in Figure 1. 
RWllt.5 
RigItt atrIaI ~xfs.sure (Fig. 1). In control patients (Group 
I). mean right atria1 pressure was 4.5 f 2.3 mm H8 during 
sinus rhythm before the first stinulation and increased 
significantly to 7.1 t 2.5 mm Hg during the first stimulation 
at IS0 beatslmin. Immediately after the termination of pat. 
in& right atrial pressure decreased to control values. With 
the second stimulation also at a rate of 150 beatslmin, right 
atrial pressure again increased significantly, to 7.9 2 2.2 mm 
Hg. The increment in right atrial pressure was the same for 
both stimulations. In verapamil-treated patients (Group 2). 
rightatrialpressurcincreasedirom4.6+0.7la7.5~1.7mm 
AYF AWF I Qolmll lQ9lrnll 
,pco.ol~ .. 1 --n.r.- 
Stimulation II increased right atrial pressure identically as 
compared with stimulation 1 and provoked different in- 
creases in median atrial wriuretic factor l&s in the two 
groups (Fig. 2). Median atria1 natriuretic factor concentra- 
ticms just before stimulation II wre I40 pp/ml (Group I) and 
121 pglml (Group 2) Ip = ns). In the untreated Group I. 
median atria1 natriuretic factor increased signilicantly Ip < 
0.01) to 488 &ml dwing stimulation II, whereas in the 
patients who received verapamil (GroupZ). the median value 
was 157 p&l; in this grwp, stimulation II caused no 
signiticant increase in atrial natriuretic factor. 
The effccr of verapomil to impair pressure-srimulured 
release of atria/ natriurericfacror is illrrsnated in Figure 3. 
During stimulation I the amount of atrial natriuretic factor 
release (expressed as delta vatues) was comparable in both 
groups (p = ns). However, in Group I Icontrol). the median 
increase due to stimulation II was 2.5 fold higher than that 
due to stimulation I (p i 0.02). In the verapamil-treated 
patients (Group 2). no significant difference between release 
of atria1 natriuretic factor due to stimulation I and II was 
seen. Thus. after administration of verapamil, the stimula- 
tory action of stimulation II was impaired in comparison 
with the effect of stimulation II in the untreated p&ma 
lGroup I) lp i 0.02). 
Cyclic guannsint mem+m+k. Median plasma cyclk 
GMP concentrations (Fig. 4) corresponded to the alterations 
in plasma atrial natriuretic factor concentrations, increasing 
during stimulation 1 from 3.1 to 4.9 pm&ml (Group I) and 
from 2.8 to 4.6 pmollml (Group 2). During aimulatiin II, 
cvclic GMP increased from 5.4 to 8.5 WnolJml in ccmtrol 
pkts and from 4.3 to 5.4 pmoVml i6 vempamil-@ated 
patients. In both gmupr, increases in median cyclic GXP 
were 1.8 pmollml after the first stimulation. In Grcup I 
lcontmll, cyclic GMP increased by 3.1 pm&ml after lhe 
second stimulation. However. in Group 2 (venpamil), me- 
dian cyclic GMP increased by only 1.1 pmoUml after stimu- 
lation II. There was a linear correlation between arrial 
natriuretic factor and cyclic GMP levels before stimulation I 
in both groups that was highly significant lr = 0.73, p < 
O.CW. 
LSscossion 
Our results indicate for the first time that the calcium 
channel antagonist vera~arnil is effective in nearly totally 
surmressinp. the secretion resrronle ofatrial natriurctic factor 
af& an abrupt increase in at&l pressure. This has MH been 
shown before in animals or humans. Because right lrial 
pressure and systemic blood pressure were not atTected by 
verapamil, it appears that cakium-dependent cellular mecb 
anisms are involved in the suppression of atria1 natriuretk 
factor secretion. Veratmmil atwuentlv not only inhibits the 
secretion that is indufed by g-side immediate increase ir8 
right atrial pressure. but alsoblocks the potentiating effect of 
r&&d siimulations on the release bf atrial natduretis 
factor. 
EtlKtSOfS&kPdRQ&drIghisWpItSS¶WillCcrr- 
melIt. uo reIe&S d at?kI *Ibisrctlc factor. Illcrements in 
right atrial pressure induce secretion of atrial natriuretic 
factor II-0 As previously shown (9). asynchronous con- 
laaupil Figme 4. Cyclic guamim mophmphat~ (cGVdP~ 
plasma concrmmdonr in both groups during right wl- 
8ricuIar rtimubtiom (Slim 1. Stim II, both fm 4 lrdn at 
I50 bat%nin,, Fwk”ts of Group I were lmlnrcd: 
Gmup 2 received 5 mg vempamit imraveacwly inwa 
diately after otimulalian I. - tia represent 
median MIU~E. Abbreviations a in Fits I. 
traction of the ventricles and atria induced by rapid ventri- 
cularpacing in padents with sinus rhythm provokes a sudden 
and reproducible increase in atrial pressure; therefore, pac- 
ing is appropriate to investigate the bdluence of drugs on 
secretion of atrial natriuretic factor. 
Wl~ereas right atrial pressure increased identically during 
both slimulations, the relcasc of atria1 nabiuretic factor 
induced by ,he second stimulation in Group I was 2.5.fold 
larger than that induced by the firs, stimulation. There 
results indicate ,ha the firs, secretory stimulus. that is. right 
atrial prersurc increment caused by stimulation 1. appears to 
have a “priming etTect” on tke release of atrial natriuretic 
factor caused by the identical second stimulus (161. 
Sec~tion of amal natrturetic factor as n eakium.depet,d- 
ent Process: tnRuena of the cakium channel Mocker venp, 
mi,. The myoendocrine eells are apparently capable ofa fast 
upward rwdation of their response to adequate secretory 
stimuli. This “priming eEect” has not been previously 
demonsttated for atrial natrbxetic factor but it is known for 
other peptide hormones, such as insulin, for example (17). 
After administration of verapamil in patients ofGroup 2. the 
second stimulation did not induce a significant release of 
atrial natriuretic factor and the “priming etTect” seen in 
Group I was blunted. Our findings are in agreement with 
data fmm other investigators [IO-12) who showed it, vitro 
enhanced secretious raies of atrial natrioretic factor after 
application of calcium agonists (for example, Bay K8Ed4) 
and demonwaled lha, lhis stimulatory action can be blocked 
by simultaneous administration of the calcium antagonist 
nifedipine. Tke agreement of our findings wvi!h t ese results 
supwnls the hypothesis that the observed etTects were due 
not to a possibk interference of verapamil with the auto- 
nomic nervous system but rather to its direct calcium 
blocking action. Furthermore, it has been shown for other 
peptide hormones that free intracellular calcium often ap 
pears to play a key role in triggering their secretion rate 
W-20). Until now, the direct influence of calcium antago- 
nists on the secretion of atrial natriuretic factor in humans 
has not been elucidated. 
In our protocol, the dose of 5 mg of vempamil showed no 
effect on right atrial and systemic arterial blood pressure, 
which indicates that the &ppression of atria1 n&b&c 
factor is due not to hemodynamic changer but rather to a 
direct interference with the cells that secrete &al natri- 
urctic factor. 
Contmtraiioos of the sewt,d meaoge;, cyclic goaaasine 
mowphwphstr. The increases in cyclic GMP, which is 
known as the second messenaer for atrial natriurctic factor 
(21.22). support the observed changes in atrial natriuretic 
factor. Between sdmulations I and II. cvclic GMP did not 
return 10 baseline level; this observation ian be explained by 
tbe apparent time dilienc~ between pxks of a:rinl na:ri- 
uretic factor and cyclic GMP and a markedly longer balf- 
time of cyclic GMP of about 30 min. as demonstrated in a 
previous study (23). The correlation between baseline levels 
of plasma cyclic GMP and atrial natriurctic factor we found 
in this study is compamble with recenlly reported data (24). 
Conclurlcmr. Our study suppons for the firs, time in 
humans the hypothesis that calcium plays a key role in the 
secretion of atrial natriuretic factor. Repeated stimulations 
of the secretory system by increase in right atrial pressure 
result in an upward rcgulalion of the release of atrial nat!i- 
uretic factor. Voltage-sensitive wlcium channel blockers 
impair stimulated wcrction of au-tat oatriuretic factor. 
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